Table 1a:
Clinical information on HIV-infected study participants on ART
| ID symbol | Age (years) | Sex | CD4* | CD8* | CD4:CD8 ratio | Plasma viral load# | Time of infection (months) | ART | Time on ART (months) |
|---|---|---|---|---|---|---|---|---|---|
| HIV+ART #1 (●) | 62 | M | 847 | 944 | 0.90 | <40 | 191 | Kivexa Reyataz |
165 |
| HIV+ART #2 (■) | 68 | M | 314 | 793 | 0.40 | <40 | 249 | Darunavir Etravirine Dolutegravir Norvir |
181 |
| HIV+ART #3 (▲) | 23 | M | 277 | 909 | 0.30 | <40 | 11 | Complera | 8 |
| HIV+ART #4 (▼) | 47 | M | 581 | 1,060 | 0.55 | <40 | 96 | Isentress Kivexa | 96 |
| HIV+ART #5 (○) | 21 | M | 796 | 399 | 1.99 | <40 | 7 | Stribild | 4 |
| HIV+ART #6 (□) | 57 | M | 539 | 1,231 | 0.40 | <40 | 252 | Truvada | 84 |
| HIV+ART #7 (◊) | 61 | M | 397 | 238 | 1.67 | <40 | 45 | Stribild | 38 |
| HIV+ART #8 (Δ) | 62 | M | 498 | 531 | 0.94 | <40 | 213 | Raltegravir Intelence Ritonavir |
134 |
| HIV+ART #9 (∇)& | 24 | M | 776 | 478 | 1.62 | <40 | 288 | Complera | 140 |
| HIV+ART #10 (♦) | 31 | M | 824 | 900 | 0.92 | <40 | 58 | Atripla | 47 |
| HIV+ART #11 (×) | 28 | F | 433 | 240 | 1.80 | <40 | 184 | Viracept Truvada |
156 |
| HIV+ART #12 (┼) | 30 | F | 833 | 445 | 1.87 | <40 | 216 | Viracept Truvada |
192 |
ID, participant identity; F, female; M, male;
*
, cells/µl;
#, HIV-RNA copies/ml; N/A, data not available;
&, Participant ART #9 (∇) was infected at birth.